Fig. 3: Enhanced HN1L promotes ESCC growth. | Cell Death & Disease

Fig. 3: Enhanced HN1L promotes ESCC growth.

From: HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma

Fig. 3

A Gene Oncology analysis (biological process) of HN1L with Coexpedia database (https://www.coexpedia.org/). B Co-expression analysis between HN1L and the markers of cell proliferation (MKI67 and PCNA) in esophageal carcinoma (ESCA) using TCGA cohort. C ESCA samples were divided into three groups based on the level of HN1L expression. D Pathway enrichment analysis of HN1L. E Cell growth assay of KYSE30 with vector or HN1L transfection. F Cell growth assay of KYSE150 with HN1L silence. G KYSE30-Vector and KYSE30-HN1L cells were transplanted subcutaneously into nude mice, and xenograft tumor weights were counted in the right panel. H Xenograft tumor experiment was performed using KYSE150-Scramble and KYSE150-shHN1L cells. I, J IHC staining with antibodies against HN1L and Ki67 was performed respectively on xenograft tumors derived from KYSE30 with HN1L overexpression (I) or KYSE150 with HN1L silence (J). Scale bar, 50 μm. In all panels, data are presented as the mean ± SD; two-sided Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page